The ABL tyrosine kinase inhibitor STI571 (Glivec) in Philadelphia positive acute lymphoblastic leukemia - promises, pitfalls and possibilities

Hematol J. 2002;3(1):2-6. doi: 10.1038/sj.thj.6200151.

Authors

Oliver G Ottmann¹, Dieter Hoelzer

Affiliation

¹ Medizinische Klinik III, Department of Hematology and Oncology, Johann Wolfgang Goethe-Universität, Frankfurt, Germany. [email protected]

PMID: 11960387
DOI: 10.1038/sj.thj.6200151

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antineoplastic Agents / administration & dosage
Antineoplastic Agents / standards
Antineoplastic Agents / therapeutic use*
Benzamides
Drug Resistance
Fusion Proteins, bcr-abl / drug effects
Fusion Proteins, bcr-abl / genetics
Humans
Imatinib Mesylate
Piperazines / administration & dosage
Piperazines / standards
Piperazines / therapeutic use*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Protein-Tyrosine Kinases / antagonists & inhibitors
Pyrimidines / administration & dosage
Pyrimidines / standards
Pyrimidines / therapeutic use*
Treatment Outcome

Substances

Antineoplastic Agents
Benzamides
Piperazines
Pyrimidines
Imatinib Mesylate
Protein-Tyrosine Kinases
Fusion Proteins, bcr-abl